

In Hospital Outcomes of Cardiogenic Shock among Patients with Acute Myocardial Infarction

FAHEEM IQBAL¹, UJALA NAZIR², FIDA MUHAMMAD³, BILAL MUSTAFA⁴, OMER SAQIB GILL⁵

¹FCPS Cardiology, Fellow MO, Punjab Institute of Cardiology, Lahore

²Medical Officer, Cardiology Department, Farooq Hospital West Wood Branch, Lahore

³Assistant Professor Cardiology, Sargodha Medical College, University of Sargodha

⁴Assistant Professor Cardiology, Dr Akbar Niazi Teaching Hospital, Islamabad

⁵Clinical Fellow National Institute of Cardiovascular Diseases (NICVD), Karachi

Corresponding Author: Fida Muhammad, Email: mfida73@yahoo.com

ABSTRACT

Aim: To evaluate in-hospital cardiogenic shock (CS) outcomes after acute myocardial infarction.

Study Design: A descriptive study.

Place and Duration: In Punjab Institute of Cardiology, Lahore for six-months duration from 18th June 2021 to 17th December 2021.

Materials and Methods: After meeting the inclusion criteria, 200 consecutive patients with cardiogenic shock after acute myocardial infarction were studied. The major group was Group I consisting of 105 (52.5%) subjects; these were CS patients with STEMI. The patients of group-II comprised of 80 (40%) subjects, these were cases with CS with Non-STEMI and patients of the group III were 15 (7.5%); with acute left bundle branch block (LBBB) in the CS setting.

Results: The mean age of the study people was 57.2 ± 29.40. The males in the studied people were 130 (65%), and women 70 (35%). In group I; 50 (47.6%) was the in-hospital mortality, group II has in-hospital mortality of 57 (71.3%) and in group III it was 7 (46.7%) cases.

Conclusions: Patients who developed cardiogenic shock afterwards acute myocardial infarction have high ratio of mortality during their stay in hospital. This is because there are more risk factors in this subset of patients.

Keywords: acute myocardial infarction, cardiogenic shock, hospital mortality, left bundle branch block.

INTRODUCTION

Despite impressive advances and treatments in the past four eras, STEMI (STEMI) supposed to be a chief public problem for health in the industrialized world¹⁻². About one million patients each year in the United States suffer from acute myocardial infarction (AMI)³⁻⁴. Since 1960, STEMI-related mortality has been steadily declining across different population groups. Cardiogenic shock (CS) occurs when more than 40% of the heart muscle is irreversibly damaged (especially anterior wall infarction)³⁻⁴. About 80% of patients with cardiogenic shock have severe left ventricular dysfunction, 20% have mechanical defects such as ventricular septal defect, mitral regurgitation and electrical complications⁵⁻⁶. CS occurs in 8.6% of patients with STEMI. It occurs in 2% of patients without STEMI. In the absence of comprehensive intervention, overall hospital survival is 30% and mortality is 70%⁷. The rationale for the study is that CS patients constitute an important population group due to their poor prognosis and the availability of various treatments that can improve their survival. CS is accountable for the mainstream of deceases following AMI⁸⁻⁹. In the literature published in Pakistan, there is little data on the outcome of CS after AMI, so this study was intended to assess the outcome of Cardiogenic shock after AMI.

METHODS

This descriptive study was held in Punjab Institute of Cardiology, Lahore for six-months duration from 18th June 2021 to 17th December 2021. After meeting the inclusion criteria, 200 consecutive patients, who developed CS after AMI, were analyzed. The major group was Group I consisting of 105 (52.5%) subjects; these were CS patients with STEMI. The patients of group-II comprised of 80 (40%) subjects, these were cases with CS with Non-STEMI and patients of the group III were 15 (7.5%); with acute left bundle branch block (LBBB) in the CS setting. All patients with cardiogenic shock who met the subsequent criteria of inclusion were registered in the analysis. 1) Patients with acute myocardial infarction diagnosed by any of the criteria listed below.

A Chest pain dependable with AMI. b) Electrocardiographic changes, i.e., ST-segment elevation ≥0.1 mV in at least 2 adjacent limb leads or ≥0.2 mV in at least 2 adjacent chest leads. c) New or possibly recent LBBB on electrocardiogram. d) Elevated cardiac enzymes.

2) Patients treated conservatively in wards. The exclusion criteria were CS occurring for reasons other than AMI. Patients with CS treated with interventional therapy were not included. Cardiogenic shock was definite as persistent hypotension (< 90 mmHg of systolic blood pressure) remains for > 30 mins with tissue hypoperfusion evidence (limbs colder than the core) at an appropriate LV filling pressure.

Data Collection and Follow Up: A complete medical history was collected, notably age, gender, smoking history, family history of ischemic heart disease, diabetes, ischemic heart disease and hypertension. Acute MI was defined according to WHO criteria and classified as associated or unrelated to ST elevation based on the absence or presence of ST elevation of minimum 1 mm in two or more contiguous leads on the first electrocardiogram. The location of acute MI has been classified as STEMI, non-STEMI, and acute LBBB. The time of first admission was definite as the arrival time in the hospital. Primary therapy of reperfusion was definite as the usage of fibrinolytic therapy given intravenously. The use of adjuvant therapy has been reported during hospitalization. The smoking status (current or non-smoker) was also specified. The mortality was categorized as in-hospital (death prior to discharge after admission to the intensive care unit). The standard treatment protocol was applied for all patient's treatment. Heart rate, blood pressure, fever, daily monitoring of patient respiratory rate; ECG changes were monitored for up to 04 days until the patient died or was discharged. All data was analyzed using SPSS (Statistical Package for Social Sciences) version 22.0 for Windows. The age of the patients is shown by calculating the mean and standard deviation. Gender and test results (heart rate, blood pressure, pyrexia, respiratory rate, ECG changes, thrombolysis) were expressed as the frequency distribution on days 1, 2, 3 and 4. At the end of day 4, survival and death were presented by calculating incidence and percentages and stratified by hypertension, diabetes, history of ischemic heart disease, smoking, family history of ischemic heart disease and dyslipidemia to address modifiers.


RESULTS

The mean age of the study people was 57.2 ± 29.40. The mean age of patients in group I was 49 ± 19.2 years, patients in group II 63.1 ± 21.4 years, patients in group III 68 ± 11.2 years.

Table-I: Clinical Presentations of the studied People

Variables	Numbers (Percentages) n=200
CS+STEMI	100(52.5%)
CS+non-STEMI	85(40%)
CS+Acute LBBB	15(7.5%)

The males in the studied people were 130 (65%), and women 70 (35%). In group I; 50 (47.6%) was the in-hospital mortality, group II has in-hospital mortality of 57 (71.3%) and in group III it was 7 (46.7%) cases.



Group I 67 (63.8%) men and 38 (36.2%) women, group II 55 (68.8%) men and 25 (31.5%) women, group III 10 (66.7%) men and 5 (33.3%) women. (Table 2).

Table-II: shows Baseline Features of the studied People

Characteristics	Numbers (Percentages) n=230
Age	35-80Years
Sex	
Male	130(65%)
Female	70(35%)
DM	100(50%)
Hypertension	80(40%)
Smokers	125(62.5%)
Hyperlipidaemias	175(87.5%)
Previous H/O IHD	103(51.5%)

The diabetics in the studied people was 100 (50%), 37 (35.2%) in group I, 52 (65%) in group II and 11 (73.3%) in group III. The total hypertensive patients in the studied individuals were 80 (40%). Of these, 28 (26.7%) belonged to group I, 47 (58.8%) to group II, and 5 (33.3%) to group III. 125 smoked (62.5%) in the study; In groups I 63(60%), group II 51(63.8%) and group III 11 (73.3%). Hyperlipidaemias was noticed in 175 (87.5%), 100 (95.2%), 64 (80%) and 9 (60%) were in groups I, II and III, respectively. The family history of IHD was seen in 103 (51.5%) had previous history of IHD (Table 2).

Streptokinase therapy has been widely used in patients with acute STEMI and LBBB and has not been used in patients with non-STEMI. Inotropic support, diuretics and other necessary precautions were taken according to the protocol of the cardiology department. Overall, 114 (57%) patients in the study population died and 86 (43%) patients survived. In-hospital mortality predictors were reduced incidence, advanced age, very low blood pressure, high Killip, and extensive MI.

DISCUSSION

Coronary artery disease is the foremost reason of mortality universally. CAD is estimated to affect 13.2 million Americans¹⁰⁻¹¹. Not all people who have had a heart attack develop CS. In fact, CS develops in less than 10% of people who have had

a heart attack¹². But when it does, it is very dangerous. The most common cause of hospital death from a heart attack is CS. In our current study, we found CS to have poor outcome¹³⁻¹⁴. AMI is the main reason of bereavement in the recentera. CS most frequently transpires as an impediment of AMI¹⁵. Patients with CS have a higher risk of death and cardiovascular complications during AMI¹⁶. Patients with CS receiving inotropic support along with other necessary support measures have significantly higher mortality after AMI compared to other patients without CS. The observations in this report are dependable with formerly printed reports indicating amplified mortality from cardiogenic shock after acute myocardial infarction¹⁷⁻¹⁸. A study by Beattie et al shows that CS is the major reason of mortality in AMI 70-90% of mortality. Previous studies have shown that progressive age, gender, diabetes mellitus and congestive heart failure are significant forecasters of endurance in cardiogenic shock patients with acute myocardial infarction¹⁹⁻²⁰. We confirmed these observations and demonstrated an association of other conditions with survival. Conservative management is not enough to further reduce mortality²¹. In the past, almost no one has survived CS. Our outcomes also highlight the necessity to recognise the causes of less hostile treatment in these patients and to progress towards better treatment approaches for acute myocardial infarction or better primary and secondary coronary protection²². Smoking, dyslipidemia, and obesity are important risk factors for STEMI. An anterior infarction is more common. Among diabetics, the likelihood of STEMI in men and women is almost equal, while the ratio of men to women in people without diabetes is 1: 6²³. One current research exhibited that amongst CS subjects who survived 30 days after STEMI, the yearly mortality rate was 3-4% which was almost the similar as in patients without shock. More effective prevention of events of coronary syndrome may reduce the overall mortality burden of CS²⁴.

CONCLUSION

Patients who developed cardiogenic shock afterwards acute myocardial infarction have high ratio of mortality during their stay in hospital. This is because there are more risk factors in this subset of patients.

REFERENCES

1. Hashmi KA, Abbas K, Hashmi AA, Irfan M, Edhi MM, Ali N, Khan A. In-hospital mortality of patients with cardiogenic shock after acute myocardial infarction; impact of early revascularization. BMC research notes. 2018 Dec;11(1):1-5.
2. Vallabhajosyula S, Dunlay SM, Prasad A, Kashani K, Sakhuja A, Gersh BJ, Jaffe AS, Holmes DR, Barsness GW. Acute noncardiac organ failure in acute myocardial infarction with cardiogenic shock. Journal of the American College of Cardiology. 2019 Apr 16;73(14):1781-91.
3. Dhruva SS, Ross JS, Mortazavi BJ, Hurley NC, Krumholz HM, Curtis JP, Berkowitz A, Masoudi FA, Messenger JC, Parzynski CS, Ngufo C. Association of use of an intravascular microaxial left ventricular assist device vs intra-aortic balloon pump with in-hospital mortality and major bleeding among patients with acute myocardial infarction complicated by cardiogenic shock. Jama. 2020 Feb 25;323(8):734-45.
4. Vallabhajosyula S, Vallabhajosyula S, Dunlay SM, Hayes SN, Best PJ, Brenes-Salazar JA, Lerman A, Gersh BJ, Jaffe AS, Bell MR, Holmes Jr DR. Sex and gender disparities in the management and outcomes of acute myocardial infarction—cardiogenic shock in older adults. In Mayo Clinic Proceedings 2020 Sep 1 (Vol. 95, No. 9, pp. 1916-1927). Elsevier.
5. Chatterjee K, Gupta T, Goyal A, Kolte D, Khera S, Shanbhag A, Patel K, Villablanca P, Agarwal N, Aronow WS, Menegus MA. Association of obesity with in-hospital mortality of cardiogenic shock complicating acute myocardial infarction. The American Journal of Cardiology. 2017 May 15;119(10):1548-54.
6. Vallabhajosyula S, Dunlay SM, Murphree DH, Barsness GW, Sandhu GS, Lerman A, Prasad A. Cardiogenic shock in takotsubo cardiomyopathy versus acute myocardial infarction: an 8-year national perspective on clinical characteristics, management, and outcomes. JACC: Heart Failure. 2019 Jun;7(6):469-76.

7. Vallabhajosyula S, Dunlay SM, Barsness GW, Rihal CS, Holmes Jr DR, Prasad A. Hospital-level disparities in the outcomes of acute myocardial infarction with cardiogenic shock. *The American Journal of Cardiology*. 2019 Aug 15;124(4):491-8.
8. Vallabhajosyula S, Ya'Qoub L, Singh M, Bell MR, Gulati R, Cheungpasitporn W, Sundaragiri PR, Miller VM, Jaffe AS, Gersh BJ, Holmes Jr DR. Sex disparities in the management and outcomes of cardiogenic shock complicating acute myocardial infarction in the young. *Circulation: Heart Failure*. 2020 Oct;13(10):e007154.
9. Vallabhajosyula S, Prasad A, Gulati R, Barsness GW. Contemporary prevalence, trends, and outcomes of coronary chronic total occlusions in acute myocardial infarction with cardiogenic shock. *IJC Heart & Vasculature*. 2019 Sep 1;24:100414.
10. Vallabhajosyula S, Prasad A, Dunlay SM, Murphree Jr DH, Ingram C, Mueller PS, Gersh BJ, Holmes Jr DR, Barsness GW. Utilization of palliative care for cardiogenic shock complicating acute myocardial infarction: a 15-year national perspective on trends, disparities, predictors, and outcomes. *Journal of the American Heart Association*. 2019 Aug 6;8(15):e011954.
11. Kubo S, Yamaji K, Inohara T, Kohsaka S, Tanaka H, Ishii H, Uemura S, Amano T, Nakamura M, Kadota K. In-hospital outcomes after percutaneous coronary intervention for acute coronary syndrome with cardiogenic shock (from a Japanese Nationwide Registry [J-PCI Registry]). *The American Journal of Cardiology*. 2019 May 15;123(10):1595-601.
12. Vallabhajosyula S, Prasad A, Sandhu GS, Bell MR, Gulati R, Eleid MF, Best PJ, Gersh BJ, Singh M, Lerman A, Holmes Jr DR. Mechanical Circulatory Support-Assisted Early Percutaneous Coronary Intervention in Acute Myocardial Infarction with Cardiogenic Shock: 10-Year National Temporal Trends, Predictors and Outcomes. *Eurointervention: Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology*. 2019 Nov 19.
13. Vallabhajosyula S, Patlolla SH, Verghese D, Ya'Qoub L, Kumar V, Subramaniam AV, Cheungpasitporn W, Sundaragiri PR, Noseworthy PA, Mulpuru SK, Bell MR. Burden of arrhythmias in acute myocardial infarction complicated by cardiogenic shock. *The American journal of cardiology*. 2020 Jun 15;125(12):1774-81.
14. Vallabhajosyula S, Payne SR, Jentzer JC, Sangaralingham LR, Yao X, Kashani K, Shah ND, Prasad A, Dunlay SM. Long-term outcomes of acute myocardial infarction with concomitant cardiogenic shock and cardiac arrest. *The American Journal of Cardiology*. 2020 Oct 15;133:15-22.
15. Jerónimo A, Ferrández-Escarabajal M, Ferrera C, Noriega FJ, Diz-Díaz J, Fernández-Jiménez R, McInerney A, Fernández-Ortiz A, Viana-Tejedor A. Cardiogenic Shock Clinical Presentation, Management, and In-Hospital Outcomes in Patients Admitted to the Acute Cardiac Care Unit of a Tertiary Hospital: Does Gender Play a Role?. *Journal of clinical medicine*. 2020 Sep 27;9(10):3117.
16. Hayiroğlu Mİ, Keskin M, Uzun AO, Yıldırım Dİ, Kaya A, Çinier G, Bozbeyoğlu E, Yıldırım Ö, Kozan Ö, Pehlivanoglu S. Predictors of in-hospital mortality in patients with ST-segment elevation myocardial infarction complicated with cardiogenic shock. *Heart, Lung and Circulation*. 2019 Feb 1;28(2):237-44.
17. Vallabhajosyula S, Kumar V, Vallabhajosyula S, Subramaniam AV, Patlolla SH, Verghese D, Ya'Qoub L, Stulak JM, Sandhu GS, Prasad A, Holmes Jr DR. Acute myocardial infarction-cardiogenic shock in patients with prior coronary artery bypass grafting: A 16-year national cohort analysis of temporal trends, management and outcomes. *International Journal of Cardiology*. 2020 Jul 1;310:9-15.
18. Aissaoui N, Puymirat E, Delmas C, Ortuno S, Durand E, Bataille V, Drouet E, Bonello L, Bonnefoy-Cudraz E, Lesmeles G, Guerot E. Trends in cardiogenic shock complicating acute myocardial infarction. *European Journal of Heart Failure*. 2020 Apr;22(4):664-72.
19. Krishnan U, Brejt JA, Schulman-Marcus J, Swaminathan RV, Feldman DN, Wong SC, Goyal P, Horn EM, Karas M, Sobol I, Minutello RM. Characteristics of hospitalizations for cardiogenic shock after acute myocardial infarction in the United States. *International Journal of Cardiology*. 2017 Oct 1;244:213-9.
20. Vallabhajosyula S, Dunlay SM, Bell MR, Miller PE, Cheungpasitporn W, Sundaragiri PR, Kashani K, Gersh BJ, Jaffe AS, Holmes DR, Barsness GW. Epidemiological trends in the timing of in-hospital death in acute myocardial infarction-cardiogenic shock in the United States. *Journal of clinical medicine*. 2020 Jul 3;9(7):2094.
21. Vallabhajosyula S, Kashani K, Dunlay SM, Vallabhajosyula S, Vallabhajosyula S, Sundaragiri PR, Gersh BJ, Jaffe AS, Barsness GW. Acute respiratory failure and mechanical ventilation in cardiogenic shock complicating acute myocardial infarction in the USA, 2000–2014. *Annals of intensive care*. 2019 Dec;9(1):1-0.
22. Shah M, Patnaik S, Patel B, Ram P, Garg L, Agarwal M, Agrawal S, Arora S, Patel N, Wald J, Jorde UP. Trends in mechanical circulatory support use and hospital mortality among patients with acute myocardial infarction and non-infarction related cardiogenic shock in the United States. *Clinical Research in Cardiology*. 2018 Apr;107(4):287-303.
23. Vallabhajosyula S, Ya'Qoub L, Kumar V, Verghese D, Subramaniam AV, Patlolla SH, Desai VK, Sundaragiri PR, Cheungpasitporn W, Deshmukh AJ, Kashani K. Contemporary national outcomes of acute myocardial infarction-cardiogenic shock in patients with prior chronic kidney disease and end-stage renal disease. *Journal of clinical medicine*. 2020 Nov 18;9(11):3702.
24. Khera R, Secemsky EA, Wang Y, Desai NR, Krumholz HM, Maddox TM, Shunk KA, Virani SS, Bhatt DL, Curtis J, Yeh RW. Revascularization practices and outcomes in patients with multivessel coronary artery disease who presented with acute myocardial infarction and cardiogenic shock in the US, 2009-2018. *JAMA Internal Medicine*. 2020 Oct 1;180(10):1317-27.